A Phase 1, Multi-Center, Open-Label, Dose De-Escalation Study of the Oncolytic Virus Talimogene Laherparepvec (T-VEC) in Paediatric Patients with Advanced Extracranial Solid Tumors

被引：0
|
作者：
Moreno, L. [1 ]
Zhang, Y. [2 ]
Bhatta, S. [3 ]
机构：
[1] Hosp Univ Nino Jesus, Clin Res Programme, Madrid, Spain
[2] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA USA
[3] Amgen Inc, Global Dev, Thousand Oaks, CA USA
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-0575
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [1] A PHASE 1 STUDY OF TALIMOGENE LAHERPAREPVEC (T-VEC) IN PEDIATRIC PATIENTS WITH ADVANCED SOLID TUMORS
    Moreno, Lucas
    Teira, Pierre
    Croop, James
    Gerber, Nicolas
    Andre, Nicolas
    Aerts, Isabelle
    Subias, Luis Gros
    De Wilde, Bram
    Yi, Min
    Chan, Edward
    Streby, Keri
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S63 - S64
  • [2] Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca).
    Chang, Kenneth J.
    Senzer, Neil N.
    Binmoeller, Kenneth
    Goldsweig, Howard
    Coffin, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Early safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)
    Yamazaki, N.
    Koga, H.
    Kojima, T.
    Tsutsumida, A.
    Namikawa, K.
    Yi, M.
    Mera, K.
    Pickett-Gies, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 107 - 107
  • [4] Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors
    Hecht, J. Randolph
    Pless, Miklos
    Cubillo, Antonio
    Calvo, Aitana
    Raman, Steven
    Liu, Chunxu
    Chan, Emily
    Chesney, Jason Alan
    Prat, Aleix
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Barker, Christopher A.
    D'Angelo, Sandra P.
    Steckler, Alexa M.
    Lian, Ming
    Wasilewski, Gloria
    Lacouture, Mario E.
    Chapman, Paul B.
    Shoushtari, Alexander Noor
    Ariyan, Charlotte Eielson
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [8] Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors
    Hecht, J. R.
    Peeters, M.
    Jimenez, M. Martin
    Pless, M.
    Cubillo, A.
    Garcia-Corbacho, J.
    Mach, N.
    Digklia, A.
    Park, H.
    Subbiah, V.
    Gorski, K.
    Anderson, A.
    Liu, C.
    Snyder, W.
    Chesney, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1390 - S1391
  • [9] A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
    Hua, Y.
    Wang, C.
    Li, F.
    Han, Y.
    Zuo, D.
    Lv, Y.
    Peng, Y.
    Chen, J.
    Yuan, R.
    Zhang, F.
    Wang, Y.
    Wu, H.
    Zhou, G.
    Wang, S.
    Li, N.
    Lu, Y.
    Lin, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S677 - S677
  • [10] Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).
    Hecht, J. Randolph
    Pless, Miklos
    Cubillo, Antonio
    Calvo, Aitana
    Chon, Hong Jae
    Liu, Chunxu
    Snyder, Wendy
    Chan, Emily
    Chaney, Marya F.
    Chesney, Jason Alan
    Prat, Aleix
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345